Impact of the National Access to Antiretroviral Program on the incidence of opportunistic infections in Thailand

International Health

Volumn 3, Issue 2, 2011, Pages 101-107

  Rojanawiwat, Archawin ^a   Tsuchiya, Naho ^b   Pathipvanich, Panita ^c   Pumpradit, Wadchara ^a   Schmidt, Wolf Peter ^b   Honda, Sumihisa ^b   Auwanit, Wattana ^a   Sawanpanyalert, Pathom ^a   Ariyoshi, Koya ^b  

^a MINISTRY OF PUBLIC HEALTH   (Thailand)

^b NAGASAKI UNIVERSITY   (Japan)

^c LAMPANG HOSPITAL   (Thailand)

Author keywords

Antiretroviral therapy; HAART; HIV; Incidence; Opportunistic infections; Thailand

Indexed keywords

FLUCONAZOLE; SULFAMETHOXAZOLE; TRIMETHOPRIM;

ADULT; ARTICLE; CD4 LYMPHOCYTE COUNT; CHEMOPROPHYLAXIS; CONTROLLED STUDY; CRYPTOCOCCAL MENINGITIS; CRYPTOCOCCOSIS; CYTOMEGALOVIRUS RETINITIS; DEMOGRAPHY; EARLY DIAGNOSIS; ENCEPHALITIS; ESOPHAGUS CANDIDIASIS; FEMALE; FOLLOW UP; HEALTH CARE ACCESS; HEALTH PROGRAM; HERPES ZOSTER; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; INFECTION PREVENTION; MAJOR CLINICAL STUDY; MALE; MYCOBACTERIUM INTRACELLULARE AVIUM; PENICILLIOSIS; PNEUMOCYSTIS PNEUMONIA; PRIORITY JOURNAL; PROSPECTIVE STUDY; SCREENING; THAILAND; TOXOPLASMOSIS; TUBERCULOSIS;

EID: 79958772059     PISSN: 18763413     EISSN: 18763405     Source Type: Journal    
DOI: 10.1016/j.inhe.2010.12.004     Document Type: Article

References (31)

1. Palella F.J., Delaney K.M., Moorman A.C., Loveless M.O., Fuhrer J., Satten G.A., et al. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV Outpatient Study Investigators. N Engl J Med 1998, 338:853-860.
2. Mocroft A., Vella S., Benfield T.L., Chiesi A., Miller V., Gargalianos P., et al. Changing patterns of mortality across Europe in patients infected with HIV-1. EuroSIDA Study Group. Lancet 1998, 352:1725-1730.
3. Egger M., Hirschel B., Francioli P., Sudre P., Wirz M., Flepp M., et al. Impact of new antiretroviral combination therapies in HIV infected patients in Switzerland: prospective multicentre study. Swiss HIV Cohort Study. BMJ 1997, 315:1194-1199.
4. WHO. Towards universal access: scaling up priority HIV/AIDS interventions in the health sector. Progress report June 2008. Geneva: World Health Organization; 2008.
5. Braitstein P., Brinkhof M.W., Dabis F., Schechter M., Boulle A., Miotti P., et al. Mortality of HIV-1-infected patients in the first year of antiretroviral therapy: comparison between low-income and high-income countries. Lancet 2006, 367:817-824.
6. Lawn S.D., Harries A.D., Anglaret X., Myer L., Wood R. Early mortality among adults accessing antiretroviral treatment programmes in sub-Saharan Africa. AIDS 2008, 22:1897-1908.
7. Chasombat S., McConnell M.S., Siangphoe U., Yuktanont P., Jirawattanapisal T., Fox K., et al. National expansion of antiretroviral treatment in Thailand, 2000-2007: program scale-up and patient outcomes. J Acquir Immune Defic Syndr 2009, 50:506-512.
8. Smit C., Geskus R., Walker S., Sabin C., Coutinho R., Porter K., et al. Effective therapy has altered the spectrum of cause-specific mortality following HIV seroconversion. AIDS 2006, 20:741-749.
9. Kaplan J.E., Hanson D., Dworkin M.S., Frederick T., Bertolli J., Lindegren M.L., et al. Epidemiology of human immunodeficiency virus-associated opportunistic infections in the United States in the era of highly active antiretroviral therapy. Clin Infect Dis 2000, 30(Suppl 1):S5-14.
10. Yazdanpanah Y., Chene G., Losina E., Goldie S.J., Merchadou L.D., Alfandari S., et al. Incidence of primary opportunistic infections in two human immunodeficiency virus-infected French clinical cohorts. Int J Epidemiol 2001, 30:864-871.
11. Holmes C.B., Losina E., Walensky R.P., Yazdanpanah Y., Freedberg K.A. Review of human immunodeficiency virus type 1-related opportunistic infections in sub-Saharan Africa. Clin Infect Dis 2003, 36:652-662.
12. Holmes C.B., Wood R., Badri M., Zilber S., Wang B., Maartens G., et al. CD4 decline and incidence of opportunistic infections in Cape Town, South Africa: implications for prophylaxis and treatment. J Acquir Immune Defic Syndr 2006, 42:464-469.
13. Badri M., Wilson D., Wood R. Effect of highly active antiretroviral therapy on incidence of tuberculosis in South Africa: a cohort study. Lancet 2002, 359:2059-2064.
14. Kumarasamy N., Solomon S., Chaguturu S.K., Cecelia A.J., Vallabhaneni S., Flanigan T.P., et al. The changing natural history of HIV disease: before and after the introduction of generic antiretroviral therapy in southern India. Clin Infect Dis 2005, 41:1525-1528.
15. Pathipvanich P., Ariyoshi K., Rojanawiwat A., Wongchoosie S., Yingseree P., Yoshiike K., et al. Survival benefit from non-highly active antiretroviral therapy in a resource-constrained setting. J Acquir Immune Defic Syndr 2003, 32:157-160.
16. Wichukchinda N., Nakayama E.E., Rojanawiwat A., Pathipvanich P., Auwanit W., Vongsheree S., et al. Protective effects of IL4-589T and RANTES-28G on HIV-1 disease progression in infected Thai females. AIDS 2006, 20:189-196.
17. Ministry of Public Health. National guidelines for the clinical management of HIV infection in children and adults. 6th ed. Thailand: Ministry of Public Health; 2000.
18. Tsuchiya N., Pathipvanich P., Yasuda T., Mukoyama Y., Rojanawiwat A., Matsubayashi T., et al. Demographic, socio-economic, behavioral and clinical factors predicting virologic failure with generic fixed-dose combination antiretroviral therapy before universal health insurance coverage in northern Thailand. Southeast Asian J Trop Med Public Health 2009, 40:71-82.
19. Ledergerber B., Egger M., Erard V., Weber R., Hirschel B., Furrer H., et al. AIDS-related opportunistic illnesses occurring after initiation of potent antiretroviral therapy: the Swiss HIV Cohort Study. JAMA 1999, 282:2220-2226.
20. Egger M., May M., Chene G., Phillips A.N., Ledergerber B., Dabis F., et al. Prognosis of HIV-1-infected patients starting highly active antiretroviral therapy: a collaborative analysis of prospective studies. Lancet 2002, 360:119-129.
21. Manosuthi W., Chaovavanich A., Tansuphaswadikul S., Prasithsirikul W., Inthong Y., Chottanapund S., et al. Incidence and risk factors of major opportunistic infections after initiation of antiretroviral therapy among advanced HIV-infected patients in a resource-limited setting. J Infect 2007, 55:464-469.
22. Saraceni V., King B.S., Cavalcante S.C., Golub J.E., Lauria L.M., Moulton L.H., et al. Tuberculosis as primary cause of death among AIDS cases in Rio de Janeiro, Brazil. Int J Tuberc Lung Dis 2008, 12:769-772.
23. Whalen C.C., Nsubuga P., Okwera A., Johnson J.L., Hom D.L., Michael N.L., et al. Impact of pulmonary tuberculosis on survival of HIV-infected adults: a prospective epidemiologic study in Uganda. AIDS 2000, 14:1219-1228.
24. Etard J.F., Ndiaye I., Thierry-Mieg M., Gueye N.F., Gueye P.M., Laniece I., et al. Mortality and causes of death in adults receiving highly active antiretroviral therapy in Senegal: a 7-year cohort study. AIDS 2006, 20:1181-1189.
25. Ghate M., Deshpande S., Tripathy S., Nene M., Gedam P., Godbole S., et al. Incidence of common opportunistic infections in HIV-infected individuals in Pune, India: analysis by stages of immunosuppression represented by CD4 counts. Int J Infect Dis 2009, 13:e1-8.
26. French N., Gray K., Watera C., Nakiyingi J., Lugada E., Moore M., et al. Cryptococcal infection in a cohort of HIV-1-infected Ugandan adults. AIDS 2002, 16:1031-1038.
27. Sriplung H., Parkin D.M. Trends in the incidence of acquired immunodeficiency syndrome-related malignancies in Thailand. Cancer 2004, 101:2660-2666.
28. d'Arminio Monforte A., Sabin C.A., Phillips A., Sterne J., May M., Justice A., et al. The changing incidence of AIDS events in patients receiving highly active antiretroviral therapy. Arch Intern Med 2005, 165:416-423.
29. Losina E., Yazdanpanah Y., Deuffic-Burban S., Wang B., Wolf L.L., Messou E., et al. The independent effect of highly active antiretroviral therapy on severe opportunistic disease incidence and mortality in HIV-infected adults in Cote d'Ivoire. Antivir Ther 2007, 12:543-551.
30. Murdoch D.M., Venter W.D., Van Rie A., Feldman C. Immune reconstitution inflammatory syndrome (IRIS): review of common infectious manifestations and treatment options. AIDS Res Ther 2007, 4:9.
31. French M.A., Lenzo N., John M., Mallal S.A., McKinnon E.J., James I.R., et al. Immune restoration disease after the treatment of immunodeficient HIV-infected patients with highly active antiretroviral therapy. HIV Med 2000, 1:107-115.